Author:
Song Aixin,Lin Xiao,Chen Xinyue
Abstract
AbstractHepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of combined and extended treatment strategies have improved the HBsAg clearance rate, and several patients achieved HBsAg clearance in clinical treatment. In addition, the durability of and clinical outcomes after HBsAg clearance have become the focus of both researchers and clinicians. This article reviews HBsAg clearance in terms of accessibility, durability, improvements in prognosis and relevant advances.
Funder
Thirteenth Five-Year Major Science and Technology Projects
Capital Health Research and Development Projects
Chinese National Natural Science Foundation
The Key R & D and transformation plan in Qinghai Province
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
Beijing Hospitals Authority Clinical medicine Development of special funding support
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献